![[IPWatchdog Logo]](https://ipwatchdog.com/wp-content/themes/IPWatchdog%20-%202023/assets/images/temp/logo-small@2x.png){kind=logo}
Kelly Anderson
Executive Director
Global Innovation Policy Center, U.S. Chamber of Commerce
Kelly Anderson is the Executive Director of Health and Drug Policy at the U.S. Chamber of Commerce’s Global Innovation Policy Center. Anderson also serves as the Staff Director for Camp Sunrise, a week-long summer camp for children who have experienced cancer.
Prior to becoming Executive Director, Anderson was Senior Director of Health and Drug Policy, leading a multi-faceted advocacy campaign to promote the importance of biopharmaceutical innovation, including through policy engagement with relevant U.S. government agencies, grassroots advocacy with the Chamber’s network of state and local affiliates, local media outreach, and in-state programming.
Prior to joining the Chamber, Anderson handled congressional affairs at the Embassy of Gabon in Washington, D.C. During her time at the Embassy, she worked with congressional staff to raise the profile of Gabon both on the Hill and throughout Washington, D.C. Prior to this, Anderson worked at the lobbying firm American Continental Group after previously interning on the Hill.
Anderson received an Executive Masters of Public Administration at the London School of Economics and Political Science. She earned her B.A. in Political Science from Drew University in Madison, NJ.
Recent Articles by Kelly Anderson
Everyone knows someone whose life has been impacted by cancer, be it a parent, a sibling, or a friend. But it is rarer, perhaps, to know a family touched by pediatric cancer. Yet, cancer is the second leading cause of death in individuals under 14, impacting nearly 10,500 children annually in the United States. Fifty years ago, a child diagnosed with cancer had a median five-year survival rate of only 58%. But, thanks to biopharmaceutical companies’ investments in discovery science, we’ve achieved medical breakthroughs that drastically improved the survival rate, with 85% of childhood cancer patients living five years or more.
June marked the 40th anniversary of the first reported AIDS case. On the anniversary, UNAIDS released a strategy to end HIV/AIDS by 2030, a goal that seemed unthinkable over 40 years ago. Yet since 1981, the innovative scientific community has delivered a series of treatments that revolutionized the outlook for HIV/AIDS patients. Those early days of 1981 were not unlike what we experienced with coronavirus last spring. Hospitals began to see cases of a mysterious pneumonia with few options for how to treat it, just as physicians across the country struggled to identify effective treatments for COVID-19 patients last March. Indeed, Dr. Anthony Fauci – who dedicated 40 years of his career to combatting HIV/AIDS – recalled “the first few years were the darkest years of my medical career, because I was working countless hours taking care of desperately ill young men.”
